BioSpace News Archive

Caring Cross announced that Boro Dropulić, Ph.D., Co-founder and Executive Director of Caring Cross, will participate in a panel discussion at the inaugural Cell and Gene Therapy Summit on April 24-25, 2023 in Brussels.

Harmony Biosciences Holdings, Inc. today announced that it will report first quarter 2023 financial results on Tuesday, May 2, 2023, before the open of the U.S. financial markets.

Apex Labs Ltd. is pleased to announce approval of SUMMIT-90. SUMMIT-90 is a landmark double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90 administered in-clinic with assisted psychotherapy for the treatment of severe depression within diagnosed PTSD.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open.

MAIA Biotechnology, Inc. (NYSE American: MAIA ) today announced preliminary survival data in the Part A safety lead-in of its ongoing phase 2 trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF ™ for the Treatment of Presbyopia.

NTT Research, Inc ., a division of NTT (TYO:9432), today announced that members of its Cryptography & Information Security (CIS) Lab and of the NTT Social Informatics Laboratories (SIL) in Tokyo, Japan co-authored 17 papers that are being presented at Eurocrypt 2023.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company TM , today announced that it will report financial results for the first quarter 2023 on Thursday, May 11, 2023.

Ondine Biomedical (OBI:LON), a Canadian life sciences company, reported that photodisinfection being developed for food processing demonstrated high efficacy against key food-borne pathogens.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title “Nasal Formulations of Metoclopramide.”